688767.SH
Hangzhou Biotest Biotech Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 38.20
+4.09%Oct 29, 2026, 08:00 UTC
Boto Bio reported 2026 first-three-quarter revenue of RMB 312 million, up 1.33% year over year, and a net loss attributable to shareholders of RMB 16.6678 million.
Source:Oct 29, 2026, 08:00 UTC
Boto Bio reported 2026 third-quarter revenue of RMB 97.4943 million, down 6.96% year over year, and a net loss attributable to shareholders of RMB 115,200.
Source:Sep 7, 2026, 02:37 UTC
Botuo Biotech announced at its 2026 interim results briefing that it will seek investment and mergers/acquisitions to open new growth tracks in the medical and health sector.
Source: